Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02068846 · ClinicalTrials.gov registry record · Phase 3
BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent
A Phase 3 study of HIV and Salivary Gland Disease, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 3
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT02068846 is a Phase 3 study of HIV and Salivary Gland Disease that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 17 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02068846, a Phase 3 study of HIV and Salivary Gland Disease, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to analyze BK viral infection in salivary gland diseases; specifically, to determine a definitive relationship between BK Virus and HIV associated salivary gland disease (HIVSGD). Participants are adults HIV+SGD+ who will be randomized 1:1 to receive BK Virus antiviral (ciprofloxacin) or placebo for 28 days. Salivary function/protein secretion will be correlated with BK polyomavirus titers. It is expected that patients with HIV+SGD+ will have elevated oral BK polyomavirus viral loads and will benefit from Ciprofloxacin.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ciprofloxacin
Study Locations (1)
North Carolina
- The University of North Carolina School of Dentistry - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02068846
The ClinicalTrials.gov registry entry for NCT02068846 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (96% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02068846 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02068846 about?
NCT02068846 is a clinical study titled "BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent". The purpose of this study is to analyze BK viral infection in salivary gland diseases; specifically, to determine a definitive relationship between BK Virus and HIV associated salivary gland disease (HIVSGD). Participants are adults HIV+SGD+ who will be randomized 1:1 to receive BK Virus antiviral (...
What is the current status of trial NCT02068846?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2014-04. Estimated completion is 2016-01.
What conditions does trial NCT02068846 study?
This clinical trial studies the following conditions: HIV, Salivary Gland Disease, Benign Lymphoepithelial Lesion.
What interventions are being tested in trial NCT02068846?
The interventions under investigation include: Placebo (DRUG), Ciprofloxacin (DRUG).
Who is sponsoring clinical trial NCT02068846?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02068846 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
COMPLETED · Phase 3
-
Training Community Members to Deliver HIV Prevention Programs to Urban Youth
COMPLETED · Phase 3
-
Effects of Biktarvy on CFR in Stable HIV Patients
COMPLETED · Phase 3
-
Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic
COMPLETED · Phase 3
-
Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.